1 - 9 out of 9Page size: 10
  1. 2021

  2. Clinical characteristics and risk factors of preventable hospital readmissions within 30 days

    Meurs, E. A. I. M., Siegert, C. E. H., Uitvlugt, E., Morabet, N. E., Stoffels, R. J., Schölvinck, D. W., Taverne, L. F., Hulshof, P. B. J. E., ten Horn, H. J. S., Noordman, P. C. W., van Es, J., van der Heijde, N., van der Ree, M. H., van den Bosch, M. A. A. J. & Karapinar-Çarkit, F., 1 Dec 2021, In: Scientific reports. 11, 1, 20172.

    Research output: Contribution to journal › Article › Academic › peer-review

  3. 2018

  4. Deep sequencing identifies hepatitis B virus core protein signatures in chronic hepatitis B patients

    van der Ree, M. H., Jansen, L., Welkers, M. R. A., Reesink, H. W., Feenstra, K. A. & Kootstra, N. A., 2018, In: Antiviral research. 158, p. 213-225

    Research output: Contribution to journal › Article › Academic › peer-review

  5. 2017

  6. Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101

    Stelma, F., van der Ree, M. H., Sinnige, M. J., Brown, A., Swadling, L., de Vree, J. M. L., Willemse, S. B., van der Valk, M., Grint, P., Neben, S., Klenerman, P., Barnes, E., Kootstra, N. A. & Reesink, H. W., 2017, In: Hepatology (Baltimore, Md.). 66, 1, p. 57-68

    Research output: Contribution to journal › Article › Academic › peer-review

  7. Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing

    van der Ree, M. H., Stelma, F., Willemse, S. B., Brown, A., Swadling, L., van der Valk, M., Sinnige, M. J., van Nuenen, A. C., de Vree, J. M. L., Klenerman, P., Barnes, E., Kootstra, N. A. & Reesink, H. W., 2017, In: Antiviral research. 146, p. 139-145

    Research output: Contribution to journal › Article › Academic › peer-review

  8. MicroRNA's in chronic hepatitis B and C virus infection

    van der Ree, M. H., 2017, 235 p.

    Research output: PhD Thesis › Phd-Thesis - Research and graduation internal

  9. Plasma MicroRNA Levels Are Associated With Hepatitis B e Antigen Status and Treatment Response in Chronic Hepatitis B Patients

    van der Ree, M. H., Jansen, L., Kruize, Z., van Nuenen, A. C., van Dort, K. A., Takkenberg, R. B., Reesink, H. W. & Kootstra, N. A., 2017, In: Journal of infectious diseases. 215, 9, p. 1421-1429

    Research output: Contribution to journal › Article › Academic › peer-review

  10. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial

    van der Ree, M. H., de Vree, J. M., Stelma, F., Willemse, S., van der Valk, M., Rietdijk, S., Molenkamp, R., Schinkel, J., van Nuenen, A. C., Beuers, U., Hadi, S., Harbers, M., van der Veer, E., Liu, K., Grundy, J., Patick, A. K., Pavlicek, A., Blem, J., Huang, M., Grint, P., & 4 othersNeben, S., Gibson, N. W., Kootstra, N. A. & Reesink, H. W., 2017, In: Lancet. 389, 10070, p. 709-717

    Research output: Contribution to journal › Article › Academic › peer-review

  11. 2014

  12. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients

    van der Ree, M. H., van der Meer, A. J., de Bruijne, J., Maan, R., van Vliet, A., Welzel, T. M., Zeuzem, S., Lawitz, E. J., Rodriguez-Torres, M., Kupcova, V., Wiercinska-Drapalo, A., Hodges, M. R., Janssen, H. L. A. & Reesink, H. W., 2014, In: Antiviral research. 111, p. 53-59

    Research output: Contribution to journal › Article › Academic › peer-review

  13. MicroRNAs: role and therapeutic targets in viral hepatitis

    van der Ree, M. H., de Bruijne, J., Kootstra, N. A., Jansen, P. L. & Reesink, H. W., 2014, In: Antiviral therapy. 19, 6, p. 533-541

    Research output: Contribution to journal › Review article › Academic › peer-review

ID: 111481